Promising results have been presented from clinical trials into a new spray to treat premature ejaculation. The researchers testing the new treatment say that is could help men suffering from P.E last 6 times longer.
That said, men who used the spray lasted an average of 3 minutes, compared with just over 30 seconds when they did not use it. Premature ejaculation is defined as ejaculation that occurs within one minute of vaginal penetration and is thought to affect up to 30% of men.
The spray, currently known as PDS502, is sprayed on the penis before sex. It is being developed by Shionagi Pharma Inc, who pay the leader of the clinical trial as a consultant. Ira Sharlip, clinical professor of urology at the University of California, has said that he is particularly excited to be involved in rigorous clinical trials for a P.E project.
Though Priligy, Jansenn-Cilag’s new pill for premature ejaculation, has been rigorously trialed, generally products sold as premature ejaculation cures promise amazing things but have little scientific data to back them up.
There have been two pivotal trials into PSD502, involving 530 men with premature ejaculation in total. They were either given a placebo spray or the real medication and were asked to administer 3 sprays to the penis, which was then wiped off before penetration. The spray contains two topical painkillers, lidocaine and prilocaine, and is described as ‘oily but not unpleasantly so’.
The men were asked to calculate their intercourse times (using a stopwatch – erotic!) and as well as reporting longer-lasting erection times, they also said that they experienced better ejaculatory control.
There were however side effects reported by their partners, with the most frequent being burning in the vaginal area.
The company are planning on applying for FDA approval in the near future.